C&EN Whitepaper
Choosing The Right Partner For Accelerated Development of Highly Potent Drug Compounds
Brought to you by Lonza
Overview

Speed to market and development efficiency have long been drivers in the pharmaceutical industry but these factors have become more important than ever, given the changing landscape of markets. This “need for speed” is particularly important as accelerated development timelines and accelerated approval mechanisms become more common. The timely manufacture and delivery of drug product for clinical trials becomes essential, particularly for complex molecules such as high-potency active pharmaceutical ingredients (HPAPIs).

Key Objectives:
  • Important factors to consider in meeting accelerated timelines
  • The importance of choosing the right partner to ensure an efficient, focused development program

Brought to you by:
Lonza
Choosing The Right Partner For Accelerated Development of Highly Potent Drug Compounds
Please complete the form to download the whitepaper.
By submitting this form, you agree to receive more information on related products and services from the American Chemical Society (ACS Publications) via email, in accordance with the ACS Privacy Policy.

Copyright © 2024 American Chemical Society | 1155 Sixteenth Street NW | Washington, DC 20036 | View our Privacy Policy